Oncopeptides (ONCO) Stock Overview
A biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
ONCO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Oncopeptides AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.50 |
| 52 Week High | SEK 6.96 |
| 52 Week Low | SEK 1.39 |
| Beta | -1.82 |
| 1 Month Change | -19.57% |
| 3 Month Change | -66.87% |
| 1 Year Change | -0.53% |
| 3 Year Change | -86.47% |
| 5 Year Change | -98.96% |
| Change since IPO | -96.52% |
Recent News & Updates
Recent updates
A Look At The Fair Value Of Oncopeptides AB (publ) (STO:ONCO)
Jul 28
Agreements In Europe And Japan Will Unlock Global Markets
Strategic agreements in Europe and potential licensing in Japan will unlock major markets, enhancing future earnings and revenue growth.An Intrinsic Calculation For Oncopeptides AB (publ) (STO:ONCO) Suggests It's 45% Undervalued
Jun 18Oncopeptides (STO:ONCO) Will Have To Spend Its Cash Wisely
Feb 29Oncopeptides (STO:ONCO) Has Debt But No Earnings; Should You Worry?
Nov 14We Think Oncopeptides (STO:ONCO) Needs To Drive Business Growth Carefully
Jul 26Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?
Mar 25Shareholder Returns
| ONCO | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -3.5% | -3.1% | -4.9% |
| 1Y | -0.5% | 3.2% | -0.8% |
Return vs Industry: ONCO underperformed the Swedish Biotechs industry which returned 3.2% over the past year.
Return vs Market: ONCO matched the Swedish Market which returned -0.8% over the past year.
Price Volatility
| ONCO volatility | |
|---|---|
| ONCO Average Weekly Movement | 15.4% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in SE Market | 12.6% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: ONCO's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ONCO's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 75 | Sofia Heigis | www.oncopeptides.com/sv |
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells.
Oncopeptides AB (publ) Fundamentals Summary
| ONCO fundamental statistics | |
|---|---|
| Market cap | SEK 591.35m |
| Earnings (TTM) | -SEK 249.58m |
| Revenue (TTM) | SEK 71.12m |
Is ONCO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONCO income statement (TTM) | |
|---|---|
| Revenue | SEK 71.12m |
| Cost of Revenue | SEK 2.45m |
| Gross Profit | SEK 68.67m |
| Other Expenses | SEK 318.25m |
| Earnings | -SEK 249.58m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 28, 2026
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 96.55% |
| Net Profit Margin | -350.94% |
| Debt/Equity Ratio | -215.1% |
How did ONCO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/22 15:49 |
| End of Day Share Price | 2026/03/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oncopeptides AB (publ) is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Erik Hultgård | Carnegie Investment Bank AB |
| Patrik Ling | DNB Carnegie |
| Erik Hultgård | DNB Carnegie |